NCT00430001View on ClinicalTrials.gov

Vinorelbine Plus (+) Trastuzumab vs Docetaxel Plus (+) Trastuzumab as 1 Line Treatment for HER2 Positive (+) Metastatic Breast Cancer

PHASE3UnknownINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

May 31, 2005

Study Completion Date

December 31, 2008

Conditions
Breast Cancer
Interventions
DRUG

docetaxel

DRUG

vinorelbine

DRUG

trastuzumab

Trial Locations (1)

2100

RECRUITING

Department of Oncology, Rigshospitalet, Copenhagen

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

collaborator

Sanofi

INDUSTRY

lead

Danish Breast Cancer Cooperative Group

OTHER